Federal Register of Legislation - Australian Government

Primary content

PB 12 of 2014 Arrangements as made
This instrument amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (No. PB 79 of 2011) to remove 16 listed brands for the listed drugs ‘Carboplatin’, ‘Cisplatin’, ‘Epirubicin’, ‘Fludarabine’, ‘Gemcitabine’, ‘Irinotecan’, ‘Mitozantrone’, ‘Oxaliplatin’ and ‘Paclitaxel’.
Administered by: Health
Registered 26 Feb 2014
Tabling HistoryDate
Tabled HR04-Mar-2014
Tabled Senate04-Mar-2014
Date of repeal 02 Mar 2014
Repealed by Division 1 of Part 5A of the Legislative Instruments Act 2003

 

PB 12 of 2014

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No. 2)

 

National Health Act 1953

___________________________________________________________________________

 

I, Kim Bessell, Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.

 

Dated 23 February 2014

 

 

 

 

 

 

 

 

 

 

 

KIM BESSELL

Assistant Secretary

Pharmaceutical Access Branch

Principal Pharmacy Advisor

Pharmaceutical Benefits Division

Department of Health

 

___________________________________________________________________

 

 

1              Name of Instrument

 

(1)                This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No.2).

 

(2)                This Instrument may also be cited as PB 12 of 2014.

2             Commencement

                This Instrument commences on 1 March 2014.

3              Amendments to PB 79 of 2011

                      Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).

 

 


Schedule 1                   Amendments

 

[1]     Schedule 1 Part 1, entry for Carboplatin in the form ‘Solution for I.V. injection 150 mg in 15 mL’ with manner of administration Injection:

omit:      

Pfizer Australia Pty Ltd

PF

MP

 

D

 

[2]     Schedule 1 Part 1, entry for Cisplatin in the forms ‘I.V. injection 100 mg in 100 mL’ and ‘I.V. injection 50 mg in 50 mL’ with manner of administration Injection:

omit:      

Pfizer Australia Pty Ltd

PF

MP

 

D

 

[3]     Schedule 1 Part 1, entry for Epirubicin in the form ‘Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL’ with manner of administration Injection/Intravesical:

omit:

Epirubicin Kabi

PK

MP

 

D

 

[4]     Schedule 1 Part 1, entry for Fludarabine in the form ‘Solution for I.V. injection 50 mg fludarabine phosphate in 2 mL’ with manner of administration Injection:

omit:

 

Solution for I.V. injection 50 mg fludarabine phosphate in 2 mL

Injection

AS‑Fludarabine

YA

MP

C3887

PB

 

 

insert:

 

 

Fludarabine Ebewe

SZ

MP

C3887

PB

Solution for I.V. injection 50 mg fludarabine phosphate in 2 mL

 

Injection

Fludarabine-Ebewe

SZ

MP

C3887

PB

[5]     Schedule 1 Part 1, entry for Gemcitabine in the forms ‘Powder for I.V. infusion 2 g (as hydrochloride)’ and ‘Powder for I.V. infusion 200 mg (as hydrochloride)’  with manner of administration Injection:

omit:      

Gemcitabine Kabi

PK

MP

 

D

 

[6]     Schedule 1 Part 1, entry for Gemcitabine in the form ‘Solution concentrate for I.V. infusion 1000 mg (as hydrochloride) in 100 mL’ with the manner of administration Injection :

omit:

 

Solution concentrate for I.V. infusion 1000 mg (as hydrochloride) in 100 mL

Injection

Gemcitabine AS

YA

MP

 

D

 

 

Gemcitabine Ebewe

 

SZ

MP

 

D

 

insert:

 

Solution concentrate for I.V. infusion 1000 mg (as hydrochloride) in 100 mL

Injection

Gemcitabine Ebewe

 

SZ

MP

 

D

 

 

[7]     Schedule 1 Part 1, entry for Gemcitabine in the form ‘Solution concentrate for I.V. infusion 200 mg (as hydrochloride) in 20 mL’ with the manner of administration Injection :

omit:

 

Solution concentrate for I.V. infusion 200 mg (as hydrochloride) in 20 mL

Injection

Gemcitabine AS

YA

MP

 

D

 

 

Gemcitabine Ebewe

 

SZ

MP

 

D

 

insert:

 

Solution concentrate for I.V. infusion 200 mg (as hydrochloride) in 20 mL

 

Injection

Gemcitabine Ebewe

 

SZ

MP

 

D

 

[8]     Schedule 1 Part 1, entry for Irinotecan in the form ‘I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL’ with the manner of administration Injection :

omit:      

Irinotecan Kabi

PK

MP

C3184

D

 

[9]     Schedule 1 Part 1, entry for Mitozantrone in the form ‘Injection 20 mg (as hydrochloride) in 10 mL’ with the manner of administration Injection :

omit:      

Pfizer Australia Pty Ltd

PF

MP

 

D

 

[10]  Schedule 1 Part 1, entry for Oxaliplatin in the form ‘Solution concentrate for I.V. infusion 50 mg in 10 mL’ with the manner of administration Injection :

omit:      

Oxaliplatin Kabi

PK

MP

C3900 C3901 C3930 C3939

D

 

[11]  Schedule 1 Part 1, entry for Paclitaxel in the form ‘Solution concentrate for I.V. infusion 100 mg in 16.7 mL’ with the manner of administration Injection :

omit:      

Paclitaxel Kabi

PK

MP

C3186 C3890 C3902 C3917  C3955 C3956

 

D

[12]  Schedule 1 Part 1, entry for Paclitaxel in the forms ‘Solution concentrate for I.V. infusion 100 mg in 16.7 mL’; ‘Solution concentrate for I.V. infusion 30 mg in 5 mL’ and ‘Solution concentrate for I.V. infusion 300 mg in 50 mL’ with the manner of administration Injection :

omit:      

 

Taxol

BQ

MP

C3186 C3890 C3902 C3917  C3955 C3956

D